• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Down Over 3%; IsoPlexis Shares Spike Higher

    12/22/22 12:28:18 PM ET
    $EVK
    $EVLV
    $ISO
    $ORIC
    Apparel
    Consumer Discretionary
    Computer peripheral equipment
    Technology
    Get the next $EVK alert in real time by email

    U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 600 points on Thursday.

    The Dow traded down 1.79% to 32,778.33 while the NASDAQ fell 3.21% to 10,365.96. The S&P 500 also fell, dropping, 2.35% to 3,787.23.

    Read Next: Market Volatility Drops Further Following Rebound In US Consumer Confidence


    Leading and Lagging Sectors


    Health care shares fell by just 0.4% on Thursday. Meanwhile, top gainers in the sector included ProQR Therapeutics N.V. (NASDAQ:PRQR), up 66%, and ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), up 63%.


    In trading on Thursday, information technology shares dipped by 3.2%.


    Top Headline

     

    The US economy expanded an annualized 3.2% on quarter in the third quarter, up from 2.9% in the second estimate.

     

    Equities Trading UP

     

    • ProQR Therapeutics N.V. (NASDAQ:PRQR) shares shot up 66% to $2.74 after the company, along with Eli Lilly, announced the expansion of their licensing and collaboration agreement of new genetic medicines. ProQR will receive an upfront payment of $75 million, plus an equity investment.
    • Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) got a boost, shooting 63% to $4.89 after the company announced it has entered into a clinical development collaboration for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer and agreed to sell about 5.38 million of its common shares at a price of $4.65 per share to Pfizer for proceeds of approximately $25 million.
    • IsoPlexis Corporation (NASDAQ:ISO) shares were also up, gaining 126% to $1.56. Berkeley Lights announced plans to acquire IsoPlexis in all-stock transaction at $57.8 million.

     

    Equities Trading DOWN

    • Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) shares tumbled 23% to $2.10. Evolv Technology announced $75 million in non-dilutive debt financing with Silicon Valley Bank.
    • Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) were down 16% to $18.83 after the company issued an update on anticipated registration path for RP-A501 in danon disease following end-of-Phase 1 FDA meeting.
    • Ever-Glory International Group, Inc. (NASDAQ:EVK) was down, falling 39% to $0.33. Ever-Glory announced voluntary delisting from the Nasdaq Global Market.


    Check This Out: Muscle Maker And 2 Other Stocks Under $1 Insiders Are Aggressively Buying


    Commodities

    In commodity news, oil traded down 0.4% to $77.99 while gold traded down 1.2% at $1,804.40.


    Silver traded down 1.4% to $23.845 on Thursday while copper fell 0.9% to $3.7765.

     



    Euro zone


    European shares were lower today. The eurozone’s STOXX 600 fell 1%, London’s FTSE 100 fell 0.41% while Spain’s IBEX 35 Index fell 0.48%. The German DAX dipped 1.33%, French CAC 40 fell 1.05% and Italy’s FTSE MIB Index dipped 1.22%.


    Industrial producer prices in Italy increased 29.4% year-over-year in November. Business investment in the UK dropped by 2.5% on quarter during the third quarter. The British economy grew by 1.9% year-over-year in the third quarter, while current account deficit narrowed to GBP 19.4 billion in the quarter.

     

    Asia Pacific Markets


    Asian markets closed mixed on Thursday, with the Japan’s Nikkei gaining 0.46% and Hong Kong’s Hang Seng Index gaining 2.71%. China’s Shanghai Composite Index fell 0.46%.


    The index of coincident economic indicators in Japan fell to 99.6 in October from 100.8 in the previous month, while index of leading economic indicators rose to 98.6 in October from 98.2 in September.

     

    Economics

     

    • US jobless claims increased by 2,000 to 216,000 in the week ending December 17, compared to market estimates of 220,000.
    • The US economy expanded an annualized 3.2% on quarter in the third quarter, up from 2.9% in the second estimate.


    Now Read This: Why Cinemark, Liberty SiriusXM And Other Oversold Majors In The Communication Services Sector Look Promising


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 102,048,470 cases with around 1,114,930 deaths. India confirmed a total of at least 44,677,590 cases and 530,680 deaths, while France reported over 39,025,730 COVID-19 cases with 160,870 deaths. In total, there were at least 659,881,370 cases of COVID-19 worldwide with more than 6,678,920 deaths.

    Get the next $EVK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVK
    $EVLV
    $ISO
    $ORIC

    CompanyDatePrice TargetRatingAnalyst
    Oric Pharmaceuticals Inc.
    $ORIC
    1/7/2026$22.00Overweight
    Piper Sandler
    Oric Pharmaceuticals Inc.
    $ORIC
    11/20/2025$25.00Outperform
    Evercore ISI
    Rocket Pharmaceuticals Inc.
    $RCKT
    11/18/2025Neutral → Underweight
    Analyst
    Oric Pharmaceuticals Inc.
    $ORIC
    11/18/2025Peer Perform
    Wolfe Research
    Oric Pharmaceuticals Inc.
    $ORIC
    9/4/2025$18.00Buy
    Guggenheim
    Rocket Pharmaceuticals Inc.
    $RCKT
    8/20/2025$10.00Neutral → Buy
    BofA Securities
    Evolv Technologies Holdings Inc.
    $EVLV
    8/15/2025$9.00Hold → Buy
    Lake Street
    Evolv Technologies Holdings Inc.
    $EVLV
    8/15/2025$10.00Buy
    TD Cowen
    More analyst ratings

    $EVK
    $EVLV
    $ISO
    $ORIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heyman Richard A. sold $80,431 worth of shares (6,700 units at $12.00), decreasing direct ownership by 8% to 41,800 units (SEC Form 4)

    4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

    1/20/26 7:19:28 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ellenbogen Michael sold $500,619 worth of shares (80,745 units at $6.20) and exercised 80,745 shares at a strike of $0.24 (SEC Form 4)

    4 - Evolv Technologies Holdings, Inc. (0001805385) (Issuer)

    1/20/26 4:20:01 PM ET
    $EVLV
    Computer peripheral equipment
    Technology

    SEC Form 4 filed by Director You Angie

    4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

    1/6/26 4:49:07 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVK
    $EVLV
    $ISO
    $ORIC
    SEC Filings

    View All

    SEC Form 6-K filed by ProQR Therapeutics N.V.

    6-K - ProQR Therapeutics N.V. (0001612940) (Filer)

    2/9/26 8:07:21 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by ProQR Therapeutics N.V.

    SCHEDULE 13D/A - ProQR Therapeutics N.V. (0001612940) (Subject)

    2/6/26 4:01:11 PM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Rocket Pharmaceuticals Inc.

    SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    1/30/26 2:46:14 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVK
    $EVLV
    $ISO
    $ORIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bjork Elisabeth bought $34,400 worth of shares (10,000 units at $3.44), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    1/6/26 4:05:11 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Revenue Officer Marshall Robert E bought $42,420 worth of shares (7,000 units at $6.06) (SEC Form 4)

    4 - Evolv Technologies Holdings, Inc. (0001805385) (Issuer)

    11/25/25 4:03:38 PM ET
    $EVLV
    Computer peripheral equipment
    Technology

    Director Charlton Kevin M. bought $85,196 worth of shares (15,000 units at $5.68) (SEC Form 4)

    4 - Evolv Technologies Holdings, Inc. (0001805385) (Issuer)

    11/21/25 4:39:17 PM ET
    $EVLV
    Computer peripheral equipment
    Technology

    $EVK
    $EVLV
    $ISO
    $ORIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on ORIC Pharmaceuticals with a new price target

    Piper Sandler initiated coverage of ORIC Pharmaceuticals with a rating of Overweight and set a new price target of $22.00

    1/7/26 9:13:12 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evercore ISI initiated coverage on ORIC Pharmaceuticals with a new price target

    Evercore ISI initiated coverage of ORIC Pharmaceuticals with a rating of Outperform and set a new price target of $25.00

    11/20/25 8:08:07 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals downgraded by Analyst

    Analyst downgraded Rocket Pharmaceuticals from Neutral to Underweight

    11/18/25 9:30:30 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVK
    $EVLV
    $ISO
    $ORIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProQR Announces Planned Changes to Board Composition

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company's next Annual General Meeting (AGM) as their terms conclude.  The planned changes to ProQR's Board composition at its 2026 AGM reflect the Company's development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planni

    2/9/26 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 2, 2026 (the "Grant Date"), ORIC granted a total of 173,800 non-qualified stock options and 28,700 restricted stock units to three new non-executive employees who began their employment with ORIC in January 2026. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. Th

    2/6/26 4:30:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will be participating in the following investor conferences in February: Guggenheim Emerging Outlook: Biotech Summit – Participating in a fireside chat on Thursday, February 12, 2026, at 10:30 a.m. ET. Management will also be participating in one-on-one meetings.Citi's 2026 Virtual Oncology Leadership Summit – Participating in a fireside chat on Wednesday, February 18, 2026, at 2:30 p.m. ET. Management will also be participating

    2/5/26 4:01:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVK
    $EVLV
    $ISO
    $ORIC
    Leadership Updates

    Live Leadership Updates

    View All

    ProQR Announces Planned Changes to Board Composition

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company's next Annual General Meeting (AGM) as their terms conclude.  The planned changes to ProQR's Board composition at its 2026 AGM reflect the Company's development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planni

    2/9/26 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransAct Appoints Dana Loof as Chief Marketing Officer to Accelerate Growth and Platform Expansion

    TransAct Technologies Incorporated (NASDAQ:TACT) ("TransAct" or the "Company"), a global leader in software-driven technology and integrated printing solutions, today announced the appointment of Dana Loof as Chief Marketing Officer. Ms. Loof will lead TransAct's global marketing organization, with a mandate to strengthen brand leadership, sharpen go-to-market execution, and accelerate adoption of the Company's growing technology portfolio. Ms. Loof has a 30-year track record leading high-growth technology companies, where she has been responsible for global marketing strategy, brand strategy and positioning, category building, revenue generation, and customer engagement initiatives. In h

    1/20/26 4:05:00 PM ET
    $EVLV
    $TACT
    Computer peripheral equipment
    Technology

    ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

    Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose Raised $244 million from top-tier healthcare specialist funds; Cash and investments of $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout for rinzimetostat Phase 3 study Expect to report multiple cli

    1/12/26 8:30:00 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVK
    $EVLV
    $ISO
    $ORIC
    Financials

    Live finance-specific insights

    View All

    Evolv Technology to Release Fourth Quarter Financial Results on March 10, 2026

    Evolv Technologies Holdings, Inc. (NASDAQ:EVLV), a leading security technology company pioneering AI-based solutions designed to help create safer experiences, today announced that the Company will release financial results for the fourth quarter of 2025 on Tuesday, March 10, 2026, after the market closes. Members of the Company's management team plan to host a live webcast at 4:30 p.m. Eastern Time on that day to discuss the financial results as well as management's outlook for the business. The conference call will be webcast live at http://ir.evolvtechnology.com. About Evolv Technology Evolv (NASDAQ:EVLV) is designed to transform human security by helping organizations detect potential

    2/2/26 8:00:00 AM ET
    $EVLV
    Computer peripheral equipment
    Technology

    ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

    Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- OR

    12/5/25 8:00:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

    Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development planned in this patient population Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025. Data in previously treated NSCLC pati

    12/5/25 1:00:00 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVK
    $EVLV
    $ISO
    $ORIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

    SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    12/16/24 7:51:51 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolv Technologies Holdings Inc.

    SC 13G/A - Evolv Technologies Holdings, Inc. (0001805385) (Subject)

    12/12/24 3:21:41 PM ET
    $EVLV
    Computer peripheral equipment
    Technology

    Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

    SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    11/14/24 5:54:12 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care